Human iPSC-Derived Cell Lines
Nexel is a leading specialist in iPSC-technology, headquartered in South-Korea and established in 2012. The company aims to help improve the research environment of researchers by enabling them produce quality products using Nexel’s cutting-edge technologies. The hallmark products manufactured by Nexel include iPSC-derived cardiomyocytes, hepatocytes, and neurocytes for drug discovery, toxicity testing, disease modeling, and regenerative medicine.
GV Research Platform (GVRP), in collaboration with Nexel will distribute Nexel’s proprietary cell lines and associated culture media in India, bringing advanced technology to the forefront of research and development in the region.
Cardiosight®– S
The Cardiosight®-S is a highly pure and electrophysiologically active population of cells, suitable for all types of experiments in the field of cardiomyocytes.
| Product Specifications | Product Applications |
|---|---|
|
|
Nexel’s human iPSC-derived Cardiomyocytes have been validated on multiple platforms and the quality control process has been optimized to test the exact settings in which customers use the product.
Hepatosight®– S
To address the limitations of current methods for assessing liver toxicity in drug development, including lack of reproducibility in human primary hepatocytes and abnormal phenotype expression in immortalized cells, in vitro research is turning to iPSC-derived hepatocytes like the Hepatosight®-S. The Hepatosight®-S is a highly pure and functionally active population of cells, suitable for all types of experiments in the field of hepatocytes.
| Product Specifications |
|---|
|
Neurosight®– S
Neuroactive drugs are a cause for seiurogenic and epileptic risk. Current methods are not able to model human neuronal activity in vitro – a problem overcome by the Neurosight®-S. The Neurosight®-S is a highly pure and functionally active population of cells, suitable for all types of experiments in the field of neurons.
| Product Specifications |
|---|
|
